Fistula failure (6 weeks) · people with ESRD receiving haemodialysis through an arteriovenous fistula
Glyceryl trinitrate patch showed no clear difference in fistula failure (6 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (6 weeks) · people with ESRD receiving haemodialysis through an arteriovenous fistula
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fistulae thromboses (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
Ticlopidine probably leads to lower fistulae thromboses (up to 1 month) compared with placebo (moderate certainty).
1 finding from 1 review
Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft
Dipyridamole showed no clear difference in graft thrombosis (up to 18 months) compared with placebo (moderate certainty).
1 finding from 1 review
Change in claudication distance from baseline (m) · intermittent claudication
1 finding from 1 review
Quality of life (change in points, SF‐36, WIQ) · intermittent claudication
1 finding from 1 review
Absolute claudication distance (change in metres) · intermittent claudication
1 finding from 1 review
Arterial revascularisation · intermittent claudication
It is very uncertain whether cilostazol changes arterial revascularisation (number of cases) compared with placebo (very low certainty).
1 finding from 1 review
Amputation · intermittent claudication
It is very uncertain whether cilostazol changes amputation (number of cases) compared with placebo (very low certainty).
1 finding from 1 review
Adverse event related to study medication ‐ headache (number of cases) · intermittent claudication
Cilostazol probably leads to higher adverse event related to study medication ‐ headache (number of cases) compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular events · intermittent claudication
Cilostazol showed no clear difference in cardiovascular event (number of cases) compared with placebo (low certainty).
1 finding from 1 review
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (4 weeks' to 180 days' · primary Raynaud's phenomenon
1 finding from 1 review